DUBLIN--(BUSINESS WIRE)--The "China Blood Product Industry Report, 2019-2025" report has been added to ResearchAndMarkets.com's offering.
In 2018, the lot release volume of Chinese blood products increased 13.5% year on year to 73.94 million bottles, of which the lot release volume of human albumin soared 13.8% year on year to 45.17 million bottles.
With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood products has been further opened.
At present, Chinese blood products are still centered on albumin, of which human albumin occupies a relatively high proportion. By the lot release volume, human albumin accounts for about 60%, followed by human immunoglobulin for intravenous injection with about 15%, human rabies immunoglobulin and tetanus immunoglobulin with more than 5% each.
The proportion of human fibrinogen, three special immunoglobulins, human prothrombin complex and coagulation factor VIII is relatively low, especially coagulation factor products, life-saving drugs for haemophilia patients, are often in shortage. The main reason is that the current utilization rate of plasma in China is low, and many companies are unable to produce such blood products. Therefore, China's blood product industry still faces big problems: how to further raise the plasma collection volume, how to expand the production scale of various products, how to improve the resource utilization, and how to alleviate the tight supply.
There are over thirty blood product manufacturers in China. Among them, China Biologic Products, Hualan Biological Engineering, Shanghai RAAS Blood Products and Beijing Tiantan Biological Products are more competitive, as they have richer blood product lines and adequate supply of raw materials from plasma stations.
In the future, China's blood product industry will see faster industry integration and higher concentration.
The report highlights the following:
- Analysis of development of China blood product industry, including policies, status quo, market structure, supply & demand, market size, and competitive landscape;
- Analysis on market segments of China blood product industry, covering human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor VIII, hepatitis B human immunoglobulin, human immunoglobulin, human prothrombin complex, Tetanus Immunoglobulin, and Human Rabies Immunoglobulin;
- Analysis of 13 blood product enterprises, including operation, revenue structure, gross margin, R & D investment, blood product business and development strategy;
- Summary & forecast and trends.
Key Topics Covered:
1. Overview of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features
2. Development of China Blood Product Industry
2.1 Related Policies
2.2 Status Quo
2.3 Market Structure
2.4 Market Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competition Pattern
3. Market Segments of China Blood Product Industry
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Bid Price
3.1.3 Market Structure
3.1.4 Competition Pattern
3.1.5 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.3 Coagulation Factor VIII
3.4 Hepatitis B Immunoglobulin
3.5 Human Immunoglobulin
3.6 Human Prothrombin Complex
3.7 Tetanus Immunoglobulin
3.8 Human Rabies Immunoglobulin
4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Strucuture
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.3 Shanghai RAAS Blood Products
4.4 Beijing Tiantan Biological Products
4.5 Zhenxing Biopharmaceutical & Chemical
4.6 Jiangxi Boya Bio-Pharmaceutical
4.7 Weiguang Biological Products
4.8 Beijing Bohui Innovation Technology
4.9 Wuhan ZhongyuanRuide Biological Products
4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.11 Shanxi Kangbao Biological Product
4.12 Green Cross China
4.13 Nanyue Biopharming Corporation Ltd.
5. Summary and Forecast
5.1 Summary
5.2 Development Trend
5.2.1 The Industry Continues to Boom
5.2.2 Industry Integration Speeds Up, Concentration Rises Further
5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.4 Plasma Volume Increases Progressively
5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness
5.2.6 Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.7 Downstream Demand Stimulates the Development of the Industry
5.2.8 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry
For more information about this report visit https://www.researchandmarkets.com/research/j4682x/china_blood?w=4
